Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF00562271 · 1 trial · 3 indications
At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) for \>7 days or Gr 3 febrile neutropenia (ANC \<1000/mm\^3, fever ≥38 degrees Celsius; Gr 4 thrombocytopenia (platelets \<25,000 cells/mm\^3); Gr ≥3 non-hematologic toxicity despite adequate medical intervention; Gr ≥3 confirmed prolonged QTc interval (\>500 milliseconds \[msec\]); confirmed cardiac troponin I ≥99 percentile of reference range; Tx related toxicities with failure to receive ≥18 days Tx in 21-day cycle or inability to resume current dose level ≤14 days.
Metabolic response demonstrated in any tumor reduction of ≥15% in tumor FDG standardized uptake value (SUV) in Cycle 1; based on the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Participant must have had a baseline PET with at least 1 tumor lesion demonstrating an FDG SUV of ≥5.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF00562271 | DRUG | 125 mg twice daily \[BID\] with food, tablet |
Inclusion Criteria: * Pancreatic, head and neck, and prostatic neoplasms, and patients with non-hematologic malignancies who have tumor appropriate for serial biopsy. * Adequate organ function, including bilirubin less than 1.5 x ULN, and \[Eastern Cooperative Oncology Group\] ECOG performance stat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
PF00562271 is an investigational small molecule being studied for the treatment of head and neck neoplasms. It was evaluated in a Phase 1 clinical trial that also included patients with pancreatic and prostatic neoplasms. The drug is not approved and remains in clinical development.
PF00562271 is a small molecule developed for oncology. Its specific molecular target has not been disclosed in the available information. The drug was studied in a Phase 1 trial for head and neck, pancreatic, and prostatic neoplasms.
PF00562271 is being developed by Verastem, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VSTM. The company conducted a Phase 1 clinical trial of the drug in patients with head and neck, pancreatic, and prostatic neoplasms.
PF00562271 is in Phase 1 clinical development. It has completed one Phase 1 trial, which enrolled 99 patients. The drug is investigational and has not been approved by regulatory authorities.
PF00562271 has one completed clinical trial, NCT00666926, titled 'Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms.' This Phase 1 study enrolled 99 patients across the United States, Australia, and Canada.
Yes, PF00562271 and PF-00562271 refer to the same investigational drug. The clinical trial NCT00666926 uses the name PF-00562271, while the drug is also referred to as PF00562271 in development records.